62 / 220
[18]
Cacicedo J, Fernandez I, Del Hoyo O, Dolado A, Gomez- Suarez J, Hortelano E, et al. Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis. Eur J Nucl Med Mol Imaging 2015;42(9):1378 e 89 .[19]
Connell CA, Corry J, Milner AD, Hogg A, Hicks RJ, Rischin D, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 2007;29(11):986 e 95 .[20]
Strobel K, Haerle SK, Stoeckli SJ, Schrank M, Soyka JD, Veit- Haibach P, et al. Head and neck squamous cell carcinoma (HNSCC) e detection of synchronous primaries with (18)F-FDG- PET/CT. Eur J Nucl Med Mol Imaging 2009;36(6):919 e 27.
[21]
Edge SB, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010. p. 21 e 67.
[22]
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer Oxf Eng 1990 2009;45(2):228 e 47.
[23]
Lee JR, Kim JS, Roh JL, Lee JH, Baek JH, Cho KJ, et al. Detection of occult primary tumors in patients with cervical me- tastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging- prospective study. Radiology 2015;274(3):764 e 71.
[24]
Barber TW, Duong CP, Leong T, Bressel M, Drummond EG, Hicks RJ. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med 2012;53(6):864 e 71.
[25]
Syed R, Bomanji JB, Nagabhushan N, Hughes S, Kayani I, Groves A, et al. Impact of combined (18)F-FDG PET/CT in head and neck tumours. Br J Cancer 2005;92(6):1046 e 50.
[26]
Branstetter BFt, Blodgett TM, Zimmer LA, Snyderman CH, Johnson JT, Raman S, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005; 235(2):580 e 6.
[27]
Takeuchi S, Khiewvan B, Fox PS, Swisher SG, Rohren EM, Bassett Jr RL, et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2014;41(5):906 e 14.
[28]
Krammer J, Schnitzer A, Kaiser CG, Buesing KA, Sperk E, Brade J, et al. (18) F-FDG PET/CT for initial staging in breast cancer patients e is there a relevant impact on treatment planning compared to conventional staging modalities? Eur Radiol 2015; 25(8):2460 e 9.
[29]
Hanamoto A, Takenaka Y, Shimosegawa E, Ymamamoto Y, Yoshii T, Nakahara S, et al. Limitation of 2-deoxy-2-[F-18]fluoro- D-glucose positron emission tomography (FDG-PET) to detect early synchronous primary cancers in patients with untreated head and neck squamous cell cancer. Ann Nucl Med 2013;27(10): 880 e 5.
[30]
Quon A, Fischbein NJ, McDougall IR, Le QT, Loo Jr BW, Pinto H, et al. Clinical role of 18F-FDG PET/CT in the man- agement of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med 2007;48(Suppl. 1):58S e 67S.
[31]
Xu GZ, Guan DJ, He ZY. (18)FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysis. Oral Oncol 2011;47(7): 560 e 5.
[32]
Yabuki K, Kubota A, Horiuchi C, Taguchi T, Nishimura G, Inamori M. Limitations of PET and PET/CT in detecting upper gastrointestinal synchronous cancer in patients with head and neck carcinoma. Eur Arch Otorhinolaryngol 2013;270(2):727 e 33.
I.S. Ryu et al. / European Journal of Cancer 63 (2016) 88
e
96
42